• English
  • 简体中文
Login Register
Current Location: Home > Marketing Drugs(EU) Feedback Help Print
Product No EMEA/H/C/000471
Brand Name Abilify
Nonproprietary Name aripiprazole
API aripiprazole
ATC Code N05AX12
Indications Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
Orphan Drug no
Generics no
Marketing Authorization Holder Otsuka Pharmaceutical Europe Ltd
Status Authorised
Authorization Date 2004-06-04
Version 34
Condition Approval no
Exceptions no
Biosimilar no
Details 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息)